← Back to Clinical Trials
Recruiting NCT06327594

NCT06327594 Assessment System of Sarcopenia in Lung Cancer Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06327594
Status Recruiting
Phase
Sponsor West China Hospital
Condition Sarcopenia
Study Type OBSERVATIONAL
Enrollment 1,500 participants
Start Date 2023-11-01
Primary Completion 2027-11

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 100 Years
Study Type OBSERVATIONAL
Interventions
ultrasound scanCT/MRI scan

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,500 participants in total. It began in 2023-11-01 with a primary completion date of 2027-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

1. To explore the diagnostic value of musculoskeletal cross-modal imaging assessment system of ultrasound combined with abdominal CT/MRI for sarcopenia in patients with lung cancer. 2. To explore the value of musculoskeletal cross-modal imaging assessment system of ultrasound combined with abdominal CT/MRI in evaluating the prognosis and the effect of nutritional support in patients with lung cancer during perioperative period. 3. To explore the value of musculoskeletal cross-modal imaging assessment system of ultrasound combined with abdominal CT/MRI in evaluating the long-term prognosis of patients with lung cancer.

Eligibility Criteria

Inclusion Criteria: 1. Hospitalized patients scheduled for radical resection of lung cancer. 2. With a CT/MRI examination within 1 week. 3. The compliance of examination was good. Exclusion Criteria: 1. Amputated arm or leg. 2. Severe oedema (oedema higher than knee level). 3. Implantable pacemaker. 4. Impaired consciousness, poor general health, or other reasons that would prevent the individual from completing the study.

Contact & Investigator

Central Contact

Xinyi Tang, Dr.

✉ tangxinyi1996@outlook.com

📞 +8615680819215

Principal Investigator

Xinyi Tang

PRINCIPAL INVESTIGATOR

Department of Medical Ultrasound, West China Hospital, Sichuan University

Frequently Asked Questions

Who can join the NCT06327594 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 100 Years, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06327594 currently recruiting?

Yes, NCT06327594 is actively recruiting participants. Contact the research team at tangxinyi1996@outlook.com for enrollment information.

Where is the NCT06327594 trial being conducted?

This trial is being conducted at Chengdu, China.

Who is sponsoring the NCT06327594 clinical trial?

NCT06327594 is sponsored by West China Hospital. The principal investigator is Xinyi Tang at Department of Medical Ultrasound, West China Hospital, Sichuan University. The trial plans to enroll 1,500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology